The opinion in support of the decision being entered today was not written
for publication and is not binding precedent of the Board.
Paper No. 53
UNITED STATES PATENT AND TRADEMARK OFFICE
__________
BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES
__________
Ex parte JAN ZAVADA, SILVIA PASTOREKOVA and
JAROMIR PASTOREK
__________
Appeal No. 2001-1970
Application No. 08/260,190
__________
ON BRIEF
__________
Before WILLIAM F. SMITH, SCHEINER, and GRIMES, Administrative Patent
Judges.
GRIMES, Administrative Patent Judge.
DECISION ON APPEAL
This is a decision on appeal under 35 U.S.C. § 134 from the examiner’s
final rejection of claims 30, 32, 35-37, and 39-48, all of the claims remaining.
Claims 30, 32, and 36 are representative and read as follows:
30. A method of treating neoplastic disease and/or pre-neoplastic
disease in a vertebrate, wherein said disease is associated with abnormal MN
gene expression comprising inhibiting the expression of MN gene by
administering a MN antisense oligonucleotide in a physiologically acceptable
carrier, wherein said MN antisense oligonucleotide is complementary to SEQ ID
NO: 5.
32. A method according to Claim 30 wherein said MN antisense
oligonucleotide is complementary to the 5’ end of the mRNA that is transcribed
from the complement of SEQ ID NO: 5.
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007